New combo therapy targets tough liver tumors
NCT ID NCT07052253
First seen Mar 21, 2026 · Last updated May 07, 2026 · Updated 7 times
Summary
This study tests a combination of two experimental drugs (AK104/AK112 and TT-00420) in 100 adults with advanced liver cancer that cannot be treated with surgery. The goal is to see if the drugs can shrink tumors and control the disease. Participants must not have had prior cancer treatment for their liver cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital Tongji Medical College Huazhong University of Science And Technology
RECRUITINGWuhan, China, 430000, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.